Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIBRANT: L. crispatus LBP for Bacterial Vaginosis
NCT06135974Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LC106 and LC115 in bacterial vaginosis (BV) (5 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Detection of LBP strains by metagenomic sequencing at 5 weeks and Adverse events at 12 weeks. Started Feb 2024; status: completed.
02
Drugs
LC106LC115
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT06135974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135974.